Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by investclubon Nov 14, 2019 8:26pm
100 Views
Post# 30353902

RE:RE:RE:RE:RE:Ph2 results

RE:RE:RE:RE:RE:Ph2 resultsClaridge wrote

Endeavor48 ... You are correct.  

If Toade1313 expects a specific news release everytime a patient is enrolled or treated, then he'll be deceived.  This is not a kindergarden.  And it wouldn't make that professional that TLT publishes that often.

What TLT can subtly do is, through different news releases, hint us about progresses, just like they did recently.  But don't expect to hear about something specific on the first 25 patients.

As for interim data @3-month, there are 2 fairly legitimate options we can expect, depending on how fast on-boarding in the US goes:

- if pace is not as fast as expected for whatever reasons, TLT could produce data related to canadian patients
- if pace goes as expected, TLT will most probably want to include data from US patients, given the exposure, the FDA, etc ...

Take also into account that the AUA meeting will be held early May.  They could also decide to synch. with it, given the high visibility they could get toward their primary audience; urologists; those that will want to integrate this technology in their future practice.  That would be fair to assume they would want to capitalize on that opportunity, to create a buzz.  That would facilitate any future discussions with big pharmas regarding distribution rights, the greater the buzz is. 

My personal bet is that we won't hear about 3-month interim data before mid-2020 and they it will include US data and that it will include enough patients 15-20) so nobody could dispute the statistical significance.  But I'd be glad to be wrong on that mid-2020 target.  Especially considering the AUA meeting in May.

We'll see.  In the meantime, discussions have taken place with sites, as per the recent news releases.  So there's little reasons to be insecure.  It's a question of time, not if.

_______________________

Endeavor48 - (11/14/2019 3:13:05 PM)

RE:RE:RE:Ph2 results
toade you're assuming because we haven't recieved an n.r on the matter,that they have only treated two so far...fwiw I was told by public relations that they would not necessarily be releasing an n.r everytime a patient is treated...Perhap's there are currently more then two treated??

Hi Claridge I believe what you think will be the coarse TLT should take after the IND and patient 1 &2 3 month results are released as initially this will say in a very loud voice we are on the right track. Yes it would become almost meaningless to release after each enrollment  and even after awhile the 3 month 100%CRs  maybe at one point groups of 5 and of course anything significant. Hand holding will stop but again only after the desired results are obvious. Claridge your posts are much appreciated.. thanks

Bullboard Posts